PARKINSON KASALLIGIDA RIVOJLANADIGAN ASORATLAR VA ULARNI NAZORAT QILISH

Authors

  • Mahliyo A. Alisherovna Toshknet davlat tibbiyot universiteti, Tibbiy radiologiya kafedrasi assistenti
  • Alibayev Davron Toshkent davlat tibbiyot universiteti, Davolash fakulteti talabasi

Keywords:

Parkinson kasalligi, dopamin yetishmovchiligi, substantia nigra, neyrodegeneratsiya, motor simptomlar, nomotor simptomlar, motor fluktuatsiyalar, diskineziya, bradikineziya, rigidlik, tremor, disfagiya, kognitiv buzilishlar, demans, depressiya, anksiyete, gallyutsinatsiya, avtonom disfunksiya, ortostatik gipotenziya, qabziyat, uyqu buzilishlari, yiqilishlar, postural instabilite, levodopa, dopamin agonistlari, COMT ingibitorlari, MAO-B ingibitorlari, amantadin, farmakoterapiya, chuqur miya stimulyatsiyasi, reabilitatsiya, fizioterapiya, nutq terapiyasi, multidisiplinar yondashuv, hayot sifati.

Abstract

Annotatsiya. Parkinson kasalligi— asosan keksa yoshda uchraydigan va markaziy asab tizimining progressiv zararlanishi bilan kechuvchi neyrodegenerativ kasallik bo‘lib, uning patogenezida substantia nigra hududidagi dopaminerg neyronlarning degeneratsiyasi yetakchi o‘rin tutadi. Ushbu jarayon natijasida dopamin tanqisligi yuzaga kelib, nafaqat klassik motor belgilar (bradikineziya, rigidlik, tremor), balki keng ko‘lamli nomotor buzilishlar ham rivojlanadi. Mazkur maqolada Parkinson kasalligida uchraydigan asosiy asoratlar — motor (motor fluktuatsiyalar, diskineziyalar, yiqilishlar) va nomotor (kognitiv buzilishlar, disfagiya, uyqu va avtonom disfunksiyalar) holatlar tizimli ravishda tahlil qilingan. Tahlillar shuni ko‘rsatadiki, uzoq muddatli Levadop terapiyasi samarali bo‘lishiga qaramay, vaqt o‘tishi bilan turli asoratlar rivojlanishiga olib keladi. Shuning uchun davolashda individual yondashuv, dori dozasini optimallashtirish hamda qo‘shimcha farmakologik vositalardan foydalanish muhim ahamiyatga ega. Bundan tashqari, zamonaviy invaziv usullar, xususan chuqur miya stimulyatsiyasi motor simptomlarni nazorat qilishda yuqori samaradorlik ko‘rsatadi, biroq ma’lum xavflarni ham o‘z ichiga oladi. Maqolada shuningdek, reabilitatsiya (jismoniy, nutq va mehnat terapiyasi), multidisiplinar yondashuv hamda statsionar davolash jarayonida yuzaga keladigan muammolar ham keng yoritilgan. Xulosa qilib aytganda, Parkinson kasalligida asoratlarni samarali boshqarish faqat kompleks, uzluksiz va individual moslashtirilgan davolash strategiyalarini qo‘llash orqali amalga oshirilishi mumkin.

References

Chaudhary, S. A., Chaudhary, S., & Rawat, S. (2025). Understanding Parkinson’s disease: current trends and its multifaceted complications. Frontiers in Aging Neuroscience, 17, 1617106. https://doi.org/10.3389/fnagi.2025.1617106

German Society for Neurology. (2024). Diagnosis and treatment of Parkinson’s disease (guideline). Neurological Research and Practice, 6(1), 28. https://doi.org/10.1186/s42466-024-00311-4

Hauser, R. A., & Benbadis, S. R. (2026). Parkinson disease treatment & management. Medscape.

Merck & Co., Inc. (2024). Parkinson disease (PD). MSD Manual Consumer Version.

Rajalingam, R., Sorrento, G., & Fasano, A. (2025). Risk of fall with device-based advanced treatments in Parkinson’s disease: a systematic review and network meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry, 96(5), 470–479. https://doi.org/10.1136/jnnp-2024-334521

Aguilar-Calderón, A. M., Reyes-Jiménez, J. A., Sánchez-Aguilar, F. J., et al. (2025). Risk of cerebrovascular events in deep brain stimulation for Parkinson’s disease focused on STN and GPi: systematic review and meta-analysis. Brain Sciences, 15(4), 413. https://doi.org/10.3390/brainsci15040413

Veilleux Carpentier, A., Malaty, I. A., LeWitt, P. A., et al. (2025). A systematic review of the Parkinson’s Foundation hospital care recommendations. Movement Disorders Clinical Practice, 12(3), 215–225. https://doi.org/10.1002/mdc3.70012

UF Department of Neurology. (2025). A systematic review of the Parkinson’s Foundation hospital care recommendations. University of Florida News.

Liang, T. W., Hurtig, H. I., & Eichler, A. F. (2026). Medical management of motor fluctuations and dyskinesia in Parkinson disease. UpToDate.

Frontiers in Aging Neuroscience. (2025). Levodopa-induced dyskinesia in Parkinson’s disease: an updated review of pharmacological treatments. Frontiers in Aging Neuroscience, 17, 1684885. https://doi.org/10.3389/fnagi.2025.1684885

Goldman, J. G. (2025). Non-motor symptoms and treatments in Parkinson’s disease. Neurologic Clinics, 43(2), 291–317. https://doi.org/10.1016/j.ncl.2024.12.008

Chahine, L., Hurtig, H. I., & Eichler, A. F. (2025). Management of nonmotor symptoms in Parkinson disease. UpToDate.

Li, F., et al. (2012). Tai chi and postural stability in patients with Parkinson’s disease. New England Journal of Medicine, 366(6), 511–519. https://doi.org/10.1056/NEJMoa1107911

Gawande, R. P., Chakwate, M., Acharya, P., et al. (2025). Physiotherapy treatment on balance impairment in patients with Parkinson’s disease: a systematic review. Journal of Neonatal Surgery, 14(6S), 7700.

Wang, T., Gong, S., Hu, W., et al. (2025). Research progress on risk factors and management strategies of dysphagia in Parkinson’s disease. West China Medical Journal, 40(5), 821–826. https://doi.org/10.7507/1002-0179.202503089

Rissardo, J. P., et al. (2025). Epidemiology of autonomic dysfunction in Parkinson’s disease (review). Medicine International, 5(6), 47. https://doi.org/10.3892/mi.2025.267

(2025). Rehabilitation strategies for sleep and autonomic symptoms in Parkinson’s disease. Current Neurology and Neuroscience Reports, 25(1), 47. https://doi.org/10.1007/s11910-025-01433-7

Marsh, L., et al. (2009). Memantine for cognitive impairment in Parkinson’s disease: a pilot study. Movement Disorders, 24(8), 1222–1225.

Goldman, J. G., Jagota, P., & Matar, E. (2025). Managing cognitive impairment in Parkinson’s disease: an update of the literature. Expert Review of Neurotherapeutics, 25(2), 189–209.

Falup-Pecurariu, C., et al. (2025). Pathophysiology and pharmacological management for sleep problems in Parkinson’s disease. Journal of Parkinson’s Disease. https://doi.org/10.1177/1877718X251371945

Al-qahtani, Z., Alasmre, L. A. A., Alasmre, H. A. A., et al. (2025). The impact of sleep disorders on nonmotor symptoms in patients with Parkinson’s disease: a systematic review. IJMDC, 9(11), 2919–2926. https://doi.org/10.24911/IJMDC.51-1762065286

Ballard, C., et al. (2014). Pimavanserin for Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 384(9946), 1129–1137. https://doi.org/10.1016/S0140-6736(14)60714-5

Borek, L. L., et al. (2025). Treating psychosis in people with Parkinson’s disease. Expert Opinion on Drug Safety, 24(5), 513–518. https://doi.org/10.1080/14740338.2025.2467813

Veilleux Carpentier, A., Malaty, I. A., LeWitt, P. A., et al. (2025). A systematic review of the Parkinson’s Foundation hospital care recommendations. Movement Disorders Clinical Practice, 12(3), 215–225. https://doi.org/10.1002/mdc3.70012

Borreli, L. (2026). Novel medication improves motor symptoms in early and advanced Parkinson’s disease. Medscape.

Meglio, M. (2025). Brain-penetrant molecule GT-02287 demonstrates reversal of glucosylsphingosine in Parkinson disease. NeurologyLive.

Wolters, E. C., & Baumann, C. R. (2025). Physical rehabilitation of patients with Parkinson’s disease. In International Compendium of Movement Disorders. Cambridge University Press.

Royal Buckinghamshire Hospital. (2025). Parkinson’s disease rehabilitation. royalbucks.co.uk.

Downloads

Published

2026-05-05